Cargando…

Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Previous studies have shown that patients with diabetes mellitus (DM) respond poorly to clopidogrel treatment. AIM: To systematically evaluate the efficacy of clopidogrel for the treatment of acute coronary syndromes or ischemic stroke in patients with or without DM. METHODS: PubMed, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Li-Rong, Ma, Qian, Feng, Lin, Qiu, Qi, Zheng, Wen, Xie, Wu-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156296/
https://www.ncbi.nlm.nih.gov/pubmed/32313612
http://dx.doi.org/10.4239/wjd.v11.i4.137
_version_ 1783522182660358144
author Liang, Li-Rong
Ma, Qian
Feng, Lin
Qiu, Qi
Zheng, Wen
Xie, Wu-Xiang
author_facet Liang, Li-Rong
Ma, Qian
Feng, Lin
Qiu, Qi
Zheng, Wen
Xie, Wu-Xiang
author_sort Liang, Li-Rong
collection PubMed
description BACKGROUND: Previous studies have shown that patients with diabetes mellitus (DM) respond poorly to clopidogrel treatment. AIM: To systematically evaluate the efficacy of clopidogrel for the treatment of acute coronary syndromes or ischemic stroke in patients with or without DM. METHODS: PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE were searched from 1980 on 27 June 2019 to identify relevant randomized controlled trials that compared the effect of a combination of clopidogrel and aspirin with aspirin alone. A random-effects meta-analysis was used to estimate the hazard ratio (HR) and its 95% confidence interval (CI). Sensitivity analysis was performed using a fixed-effect model. The I(2) statistic was used to evaluate the heterogeneity of the study data. RESULTS: Six randomized controlled trials, comprising 43352 participants (13491 with and 29861 without DM) who had received antiplatelet therapy for ≥ 3 mo, were included in the meta-analysis. Compared with aspirin alone, a combination of clopidogrel and aspirin significantly reduced the risk of any cardiovascular event in patients without DM (HR = 0.78, 95%CI: 0.71–0.86, P < 0.001; I(2) = 23%, P = 0.26). Clopidogrel plus aspirin also significantly reduced cardiovascular risk in patients with DM, although the effect was smaller (HR = 0.89, 95%CI: 0.81–0.99, P = 0.030; I(2) = 0%, P = 0.74). Nevertheless, there was no significant difference in the efficacy of clopidogrel at reducing the risk of cardiovascular events in patients with DM vs those without (P for interaction = 0.062). CONCLUSION: Thus, the present study shows that the addition of clopidogrel to aspirin significantly lowers cardiovascular risk in patients with or without DM who have experienced ischemic cardiovascular disease. The beneficial effect of the addition of clopidogrel to aspirin for patients with DM was lower than that in patients without DM, although the modifying effect of DM did not reach significance.
format Online
Article
Text
id pubmed-7156296
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-71562962020-04-20 Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials Liang, Li-Rong Ma, Qian Feng, Lin Qiu, Qi Zheng, Wen Xie, Wu-Xiang World J Diabetes Systematic Reviews BACKGROUND: Previous studies have shown that patients with diabetes mellitus (DM) respond poorly to clopidogrel treatment. AIM: To systematically evaluate the efficacy of clopidogrel for the treatment of acute coronary syndromes or ischemic stroke in patients with or without DM. METHODS: PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE were searched from 1980 on 27 June 2019 to identify relevant randomized controlled trials that compared the effect of a combination of clopidogrel and aspirin with aspirin alone. A random-effects meta-analysis was used to estimate the hazard ratio (HR) and its 95% confidence interval (CI). Sensitivity analysis was performed using a fixed-effect model. The I(2) statistic was used to evaluate the heterogeneity of the study data. RESULTS: Six randomized controlled trials, comprising 43352 participants (13491 with and 29861 without DM) who had received antiplatelet therapy for ≥ 3 mo, were included in the meta-analysis. Compared with aspirin alone, a combination of clopidogrel and aspirin significantly reduced the risk of any cardiovascular event in patients without DM (HR = 0.78, 95%CI: 0.71–0.86, P < 0.001; I(2) = 23%, P = 0.26). Clopidogrel plus aspirin also significantly reduced cardiovascular risk in patients with DM, although the effect was smaller (HR = 0.89, 95%CI: 0.81–0.99, P = 0.030; I(2) = 0%, P = 0.74). Nevertheless, there was no significant difference in the efficacy of clopidogrel at reducing the risk of cardiovascular events in patients with DM vs those without (P for interaction = 0.062). CONCLUSION: Thus, the present study shows that the addition of clopidogrel to aspirin significantly lowers cardiovascular risk in patients with or without DM who have experienced ischemic cardiovascular disease. The beneficial effect of the addition of clopidogrel to aspirin for patients with DM was lower than that in patients without DM, although the modifying effect of DM did not reach significance. Baishideng Publishing Group Inc 2020-04-15 2020-04-15 /pmc/articles/PMC7156296/ /pubmed/32313612 http://dx.doi.org/10.4239/wjd.v11.i4.137 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Systematic Reviews
Liang, Li-Rong
Ma, Qian
Feng, Lin
Qiu, Qi
Zheng, Wen
Xie, Wu-Xiang
Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials
title Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials
title_full Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials
title_fullStr Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials
title_full_unstemmed Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials
title_short Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials
title_sort long-term effect of clopidogrel in patients with and without diabetes: a systematic review and meta-analysis of randomized controlled trials
topic Systematic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156296/
https://www.ncbi.nlm.nih.gov/pubmed/32313612
http://dx.doi.org/10.4239/wjd.v11.i4.137
work_keys_str_mv AT lianglirong longtermeffectofclopidogrelinpatientswithandwithoutdiabetesasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT maqian longtermeffectofclopidogrelinpatientswithandwithoutdiabetesasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT fenglin longtermeffectofclopidogrelinpatientswithandwithoutdiabetesasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT qiuqi longtermeffectofclopidogrelinpatientswithandwithoutdiabetesasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT zhengwen longtermeffectofclopidogrelinpatientswithandwithoutdiabetesasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT xiewuxiang longtermeffectofclopidogrelinpatientswithandwithoutdiabetesasystematicreviewandmetaanalysisofrandomizedcontrolledtrials